BiotechTube

VHB937

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Amyotrophic Lateral Sclerosis (ALS)

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Trial Timeline

Oct 17, 2024 → Jul 7, 2028

NCT ID
NCT06643481

About VHB937

VHB937 is a phase 2 stage product being developed by Novartis for Amyotrophic Lateral Sclerosis (ALS). The current trial status is active. This product is registered under clinical trial identifier NCT06643481. Target conditions include Amyotrophic Lateral Sclerosis (ALS).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06643481Phase 2Active

Competing Products

20 competing products in Amyotrophic Lateral Sclerosis (ALS)

See all competitors
ProductCompanyStageHype Score
AL001 + PlaceboAlectorPhase 2
44
89Zr-DFO-AP-101Eli LillyPhase 1
33
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
Perampanel + Placebo Oral TabletEisaiPre-clinical
23
E0302 (mecobalamin)EisaiPhase 2/3
65
E0302 (mecobalamin) + E0302 (mecobalamin) + PlaceboEisaiPhase 2/3
65
methylcobalamin + saline solutionEisaiPhase 3
77
ONO-2506POOno PharmaceuticalPhase 2
52
ONO-2506PO + ONO-2506POOno PharmaceuticalPhase 2
52
ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mgZydus LifesciencesPhase 2
52
LY4256984 + PlaceboEli LillyPhase 1
33
TCH346NovartisPhase 2
52
TCH346NovartisPhase 2
52
TCH346NovartisPhase 2
52
BLZ945NovartisPhase 2
52
TRO19622RochePhase 2/3
65
Olesoxime + Placebo Comparator + RiluzoleRochePhase 3
77
Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part)PfizerPhase 1/2
40
Celecoxib + Creatine + MinocyclinePfizerPhase 2
51
DNL747 + PlaceboSanofiPhase 1
32

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85